Beyfortus is a medicine used to prevent serious lower respiratory tract (lung) disease caused by respiratory syncytial virus (RSV) in newborns and children during their first RSV season. Beyfortus contains the active substance nirsevimab.
Therapeutic Indication
### Therapeutic indication Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: i. Neonates and infants during their first RSV season. ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see section 5.1). Beyfortus should be used in accordance with official recommendations. Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: i. Neonates and infants during their first RSV season. ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see section 5.1). Beyfortus should be used in accordance with official recommendations.
Therapeutic Area (MeSH)
N/AATC Code
J06BD08
ATC Item
nirsevimab
Pharmacotherapeutic Group
Immune sera and immunoglobulins
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| nirsevimab | N/A | 尼塞韦单抗 |
EMA Name
Beyfortus
Medicine Name
Beyfortus
Aliases
N/A
